0001213900-23-021454 | 10-K | XBRL Viewer

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2022	Feb. 28, 2023	Jun. 30, 2022
Document Information Line Items
Entity Registrant Name	Bluejay Diagnostics, Inc.
Trading Symbol	BJDX
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		20,459,057
Entity Public Float			$ 21,361,484
Amendment Flag	false
Entity Central Index Key	0001704287
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-41031
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-3552922
Entity Address, Address Line One	360 Massachusetts Avenue,
Entity Address, Address Line Two	Suite 203
Entity Address, City or Town	Acton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01720
City Area Code	(844)
Local Phone Number	327-7078
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Auditor Firm ID	392
Auditor Name	Wolf & Company, P.C.
Auditor Location	Boston, Massachusetts

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 10,114,990	$ 19,047,778
Prepaid expenses and other current assets	1,673,480	1,612,708
Total current assets	11,788,470	20,660,486
Property and equipment, net	1,232,070	337,366
Operating lease right-of-use assets	465,514
Other non-current assets	35,211	21,019
Total assets	13,521,265	21,018,871
Current liabilities:
Accounts payable	635,818	295,778
Operating lease liability, current	168,706
Accrued expenses and other current liabilities	835,730	341,384
Total current liabilities	1,640,254	637,162
Operating lease liability, non-current	323,915
Other non-current liabilities	15,823
Total liabilities	1,979,992	637,162
Commitments and Contingencies (See Note 13)
Stockholders’ equity:
Common stock, $0.0001 par value; 100,000,000 shares authorized; 20,215,288 and 20,112,244 shares issued and outstanding at December 31, 2022 and 2021, respectively	2,022	2,011
Additional paid-in capital	28,536,353	28,074,484
Accumulated deficit	(16,997,102)	(7,694,786)
Total stockholders’ equity	11,541,273	20,381,709
Total liabilities and stockholders’ equity	$ 13,521,265	$ 21,018,871

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	20,215,288	20,112,244
Common stock, shares outstanding	20,215,288	20,112,244

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 249,040
Cost of sales	200,129
Gross Profit	48,911
Operating expenses:
Research and development	4,152,152	1,147,955
General and administrative	4,763,114	1,792,482
Marketing and business development	451,421	289,726
Total operating expenses	9,366,687	3,230,163
Operating loss	(9,317,776)	(3,230,163)
Other income (expense):
Interest expense, net of amortization of premium		(367,459)
Impairment of property and equipment	(237,309)
State grant income		75,000
Other income, net	258,137	34,324
Total other income (expense), net	20,828	(258,135)
Net loss	$ (9,296,948)	$ (3,488,298)
Net loss per share - Basic and diluted (in Dollars per share)	$ (0.46)	$ (0.41)
Weighted average common shares outstanding:
Basic and diluted (in Shares)	20,163,915	8,522,422

Consolidated Statements of Operations (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net loss per share - Basic and diluted (in Dollars per share)	$ (0.46)	$ (0.41)
Basic and diluted (in Shares)	20,163,915	8,522,422

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Statements of Changes in Redeemable Preferred Stock and Stockholders’ Equity (Deficit) - USD ($)	Series A Redeemable, Convertible Preferred Stock	Series B Redeemable, Convertible Preferred Stock	Series C Redeemable, Convertible Preferred Stock	Series D Redeemable, Convertible Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2020	$ 1,077,303	$ 1,800,347	$ 1,000,465		$ 315		$ (4,206,488)	$ (4,206,173)
Balance (in Shares) at Dec. 31, 2020	10,600	5,187	636		3,147,200
Exercise of common stock warrants					$ 471	140,990		141,461
Exercise of common stock warrants (in Shares)					4,715,836
Accretion of redeemable, convertible preferred stock to redemption value	73,912	33,994	19,961			(127,866)		(127,866)
Conversion of convertible debentures into Series D preferred stock				$ 4,036,535
Conversion of convertible debentures into Series D preferred stock (in Shares)				4,500
Conversion of redeemable, convertible preferred stock into common stock	$ (1,151,215)	$ (1,834,341)	$ (1,020,426)	$ (4,036,535)	$ 708	8,041,809		8,042,517
Conversion of redeemable, convertible preferred stock into common stock (in Shares)	(10,600)	(5,187)	(636)	(4,500)	7,084,323
Fair value of warrants issued for services						180,339		180,339
Fair value of warrants issued to placement agent in relation to the Convertible debentures						166,816		166,816
Conversion of Amended 2017 Convertible Notes into common stock					$ 58	579,942		580,000
Conversion of Amended 2017 Convertible Notes into common stock (in Shares)					580,000
Reclassification of Series B Warrants						145,953		145,953
Stock-based compensation expense						68,458		68,458
Issuance of common stock from exercise of stock options					$ 6	22,617		22,623
Issuance of common stock from exercise of stock options (in Shares)					56,385
Issuance of common stock in initial public offering, net of offering costs of $2,750,601					$ 216	18,855,663		18,855,879
Issuance of common stock in initial public offering, net of offering costs of $2,750,601 (in Shares)					2,160,000
Issuance of common stock from exercise of warrants					$ 237	(237)
Issuance of common stock from exercise of warrants (in Shares)					2,368,500
Net loss							(3,488,298)	(3,488,298)
Balance at Dec. 31, 2021					$ 2,011	28,074,484	(7,694,786)	20,381,709
Balance (in Shares) at Dec. 31, 2021					20,112,244
Impact of adoption of ASC 842							(5,368)	(5,368)
Impact of adoption of ASC 842 (in Shares)
Stock-based compensation expense						433,004		433,004
Stock-based compensation expense (in Shares)
Exercise of stock options					$ 7	28,869		28,876
Exercise of stock options (in Shares)					62,944
Exercise of common stock Series B Warrants					$ 4	(4)
Exercise of common stock Series B Warrants (in Shares)					40,100
Net loss							(9,296,948)	(9,296,948)
Balance at Dec. 31, 2022					$ 2,022	$ 28,536,353	$ (16,997,102)	$ 11,541,273
Balance (in Shares) at Dec. 31, 2022					20,215,288

Statements of Changes in Redeemable Preferred Stock and Stockholders’ Equity (Deficit) (Parentheticals) $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($)
Statement of Stockholders' Equity [Abstract]
Net of offering costs	$ 2,750,601

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (9,296,948)	$ (3,488,298)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	156,598	145,719
Stock-based compensation expense	433,004	68,458
Amortization of right-of-use assets	149,770
Impairment of property and equipment	237,309
Loss on disposal of property and equipment	137
Issuance of warrants for service		180,339
Gain on forgiveness of note payable, Paycheck Protection Program		(5,000)
Non-cash interest expense		227,007
Gain on revaluation of derivative warrant liability		(9,676)
Changes in operating assets and liabilities:
Inventory		84,762
Prepaid expenses and other current assets	(40,772)	(1,551,637)
Non-current assets	(14,192)	(21,019)
Accounts payable	298,881	(79,150)
Due to related party	(2,000)	(123,102)
Accrued expenses	336,620	204,839
Net cash used in operating activities	(7,741,593)	(4,366,758)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(1,199,270)	(23,947)
Net cash used in investing activities	(1,199,270)	(23,947)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of principal on notes payable		(289,617)
Payments of convertible debenture issuance costs		(562,842)
Proceeds from initial public offering, net of offering costs		18,855,879
Proceeds from issuance of convertible debentures		4,500,000
Payments on note payable, Paycheck Protection Program		(9,000)
Proceeds from exercise of common stock warrants		9,079
Payments of deferred offering costs	(20,000)
Payment of finance lease	(801)
Proceeds from exercise of stock options	28,876	22,623
Net cash provided by financing activities	8,075	22,526,122
(Decrease) increase in cash and cash equivalents	(8,932,788)	18,135,417
Cash and cash equivalents, beginning of year	19,047,778	912,361
Cash and cash equivalents, end of year	10,114,990	19,047,778
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND NON-CASH FINANCING ACTIVITIES
Interest paid	364	150,228
Exercise of warrants through debt principal conversion		132,383
Conversion of convertible debentures into preferred stock		4,500,000
Conversion of preferred stock into common stock		8,505,982
Conversion of amended 2017 convertible notes		580,000
Reclassification of derivative warrant liability into additional paid-in capital		145,953
Fair value of warrants issued to placement agent in relation to the Convertible debentures		166,816
Fair value of warrants for common stock issued for services		180,339
Fair value of warrants issued to underwriters		2,939,327
Liabilities incurred for the purchase of property and equipment	41,159
Series A redeemable, convertible preferred stock
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND NON-CASH FINANCING ACTIVITIES
Accretion of Series redeemable, convertible preferred stock dividend		17,667
Accretion of Series A redeemable, convertible preferred stock issuance costs and fair value adjustment		56,245
Series B redeemable, convertible preferred stock
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND NON-CASH FINANCING ACTIVITIES
Accretion of Series redeemable, convertible preferred stock dividend		31,258
Accretion of Series redeemable, convertible preferred stock issuance costs		2,736
Series C redeemable, convertible preferred stock
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND NON-CASH FINANCING ACTIVITIES
Accretion of Series redeemable, convertible preferred stock dividend		16,727
Accretion of Series redeemable, convertible preferred stock issuance costs		$ 3,234

Nature of Operations and Basis of Presentation

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

NATURE OF OPERATIONS AND BASIS OF PRESENTATION

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Business

Bluejay Diagnostics, Inc. (“Bluejay” and/or the “Company”) is a medical diagnostics company developing rapid tests using whole blood on our Symphony technology platform (“Symphony”) to improve patient outcomes in critical care settings. The Company’s Symphony platform is a combination of Bluejay’s intellectual property (“IP”) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges that if cleared, authorized, or approved by the U.S. Food and Drug Administration (the “FDA”), can provide a solution to a significant market need in the United States. Clinical trials indicate the Symphony device produces laboratory-quality results in less than 20 minutes in critical care settings, including Intensive Care Units (“ICUs”) and Emergency Rooms (“ERs”), where rapid and reliable results are required.

Bluejay’s first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. IL-6 is a clinically established inflammatory biomarker, considered a ‘first-responder,’ for assessment of severity of infection and inflammation across many disease indications, including sepsis. A current challenge of healthcare professionals is the excessive time and cost associated determining a patient’s level of severity at triage and the Symphony IL-6 test has the ability to consistently monitor this critical care biomarker with rapid results.

In the future Bluejay plans to develop additional tests for Symphony including two cardiac biomarkers (hsTNT and NT pro-BNP) as well as other tests using the Symphony platform. The Company does not yet have regulatory clearance for its Symphony products, and its Symphony products will need to receive regulatory authorization from the FDA in order to be marketed as a diagnostic product in the United States.

Bluejay’s operations to date have been funded primarily through the proceeds of the Company’s initial public offering (the “IPO”) in November 2021 (the “IPO Date”).

On June 4, 2021, the Company formed Bluejay Spinco, LLC, a wholly-owned subsidiary of the Company, for purposes of further development of the Company’s ALLEREYE diagnostic test. ALLEREYE is a point-of-care device offering healthcare providers a solution for diagnosing Allergic Conjunctivitis.

Initial Public Offering

The Company completed its initial public offering (the “IPO”) in November 2021 (“IPO Date”), whereby it sold 2,160,000 Units at a price of $10.00, with each Unit consisting of one share of the Company’s common stock, one warrant to purchase one share of common stock at an exercise price of $7.00 per share (“Class A Warrant”), and one warrant to purchase one share of common stock at an exercise price of $10.00 (“Class B Warrant”) (collectively, a “Unit”). Each warrant contained within the Units is exercisable until the fifth anniversary of the IPO Date, however, holders of Class B Warrants may exercise such warrants on a “cashless” basis after the earlier of (i) 10 trading days from closing date of the offering or (ii) the time when $10.0 million of volume is traded in the Company’s common stock, if the volume weighted average price of the Company’s common stock on any trading day on or after the closing date of the offering fails to exceed the exercise price of the Class B Warrant (subject to adjustment as described in the warrant agreement). Additionally, the underwriter of the IPO exercised their overallotment option, solely with respect to the Class A Warrants and Class B Warrants, shortly after the IPO Date which resulted in an additional issuance of 324,000 Class A Warrants and 324,000 Class B Warrants. The gross proceeds from the IPO were approximately $21.6 million and were offset by $2.8 million in offering costs.

Risks and Uncertainties

The Company is subject to a number of risks similar to other companies in its industry, including rapid technological change, competition from larger biotechnology companies and dependence on key personnel. The Company is also impacted by inflationary pressures and global supply chain disruptions currently impacting many companies.

On October 25, 2022, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price for its common stock had been below $1.00 for the previous 30 consecutive business days and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. The Company intends to take all reasonable measures available to achieve compliance and allow for continued listing on the Nasdaq Capital Market. However, there can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria.

Going Concern

The Consolidated Financial Statements for the years ended December 31, 2022 and 2021 were prepared under the assumption that the Company will continue as a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business. However, the Company has incurred net losses since its inception, and has negative cash flows from operations and will need additional funding to complete planned development efforts. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The Company had cash and cash equivalents of $10.1 million at December 31, 2022. It continues to develop the Symphony device and its first test for the measurement of IL-6. It remains committed to obtaining FDA clearance and has expanded clinical trials to obtain additional data to support its de novo FDA submission, while also continuing to build its manufacturing operations with its CMOs. Current cash resources and expected operating expenses are considered in determining its liquidity requirement; as well as $1.6 million of current liabilities on its balance sheet at December 31, 2022 and capital commitments of approximately $2 million during 2023 (see Notes 12 and 13). Given the Company’s current plans, the Company estimates cash resources will be sufficient to fund its operations through the fourth quarter of 2023. The Company will need additional capital to fund its planned operations for the next 12 months.

The Company may seek to raise such additional capital through public or private equity offerings, grant financing and support from governmental agencies, convertible debt, collaborations, strategic alliances and distribution arrangements. Additional funds may not be available when it needs them on terms that are acceptable to them, or at all. If adequate funds are not available, it may be required to delay or reduce the scope of its research or development programs, its commercialization efforts or its manufacturing commitments and capacity. In addition, if it raises additional funds through collaborations, strategic alliances or distribution arrangements with third parties, it may have to relinquish valuable rights to its technologies or future revenue streams.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles in the United States (“GAAP”) and include all adjustments necessary for the presentation of the Company’s consolidated financial position, results of operations and cash flows for the periods presented. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

On June 7, 2021, the Company’s Board of Directors declared a stock dividend of 2.15 shares of common stock for every share of common stock. This stock dividend was deemed a large stock dividend and was treated as a 1-for-3.15 stock split. The common stock shares and per share amounts (other than authorized shares) in these consolidated financial statements and related notes have been retroactively restated to reflect the stock dividend for all periods presented.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. The Company believes judgment is involved in accounting for the fair value-based measurement of stock-based compensation, accruals, convertible notes and warrants. The Company evaluates its estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the condensed consolidated financial statements.

Financial Statement Reclassifications

Certain balances in the prior year consolidated financial statements have been reclassified to conform to the presentation in the current year consolidated financial statements.

Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents, consisting of highly liquid money market are carried at fair market value which approximates cost.

Revenue Recognition

The Company recognizes revenue under the core principles of depicting the transfer of control to the Company’s customers in an amount reflecting the consideration to which the Company expected to be entitled. In order to achieve that core principle, the Company applies the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in that contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied.

The Company recognizes revenue when performance obligations under the terms of the contract with the customer are satisfied and are recognized at a point in time, which is also when control is transferred. When the Company performs shipping and handling activities after the transfer of control to the customer (e.g. when control transfers prior to delivery), they are considered fulfillment activities and, accordingly, the costs are accrued for when the related revenue is recognized. Sales tax and valued added taxes collected from the customers relating to product sales and remitted to governmental authorities are excluded from revenues.

Leases

Effective January 1, 2022, the Company adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) ASC 842, Leases (“ASC 842”). The Company has adopted ASC 842 using the optional transition method and, as a result, there have been no reclassification of prior comparable periods due to this adoption.

The Company has arrangements involving the lease of facilities. Under ASC 842, at inception of the arrangement, the Company determines whether the contract is or contains a lease and whether the lease should be classified as an operating or a financing lease. This determination, among other considerations, involves an assessment of whether the Company can control the underlying asset and have the right to obtain substantially all to the economic benefits or outputs from the asset.

The Company recognizes right-of-use (“ROU”) assets and lease liabilities as of the lease commencement date based on the net present value of the future minimum lease payments over the lease term. ASC 842 requires the leases to use the rate implicit in the lease unless it is not readily determinable and then it may use its incremental borrowing rate (“IBR”) to discount the future minimum lease payments. Most of the Company’s leases do not provide an implicit rate; therefore, the Company uses its IBR to discount the future minimum lease payments. The Company determines its IBR with its credit rating and other economic information available as of the commencement date, as well as the identified lease term. During the assessment of the lease term, the Company considers its renewal options and extensions within the arrangements and the Company includes these options when it’s reasonably certain to extend the term of the lease.

The Company leases include both lease and non-lease components. Consideration is allocated to the lease and non-lease components based on estimated standalone prices. The Company has elected to exclude non-lease components from the calculation of its ROU assets and lease liabilities.

The Company has lease arrangements that contain incentives for tenant improvements as well as fixed rent escalation clauses. For contracts with tenant improvement incentives that are determined to be leasehold improvements and the Company is reasonably certain to exercise, it records a reduction to the lease liability and amortizes the incentive over the identified term of the lease as a reduction to rent expense. The Company records rental expense on a straight-line basis over the identified lease term on contracts with rent escalation clauses.

Finance leases are not material to the Company’s consolidated financial statements.

Concentration of Credit Risk

Cash, and cash equivalents consist of financial instruments that potentially subject the Company to a concentration of credit risk in the event of a default by the related financial institution holding the securities, to the extent of the value recorded in the balance sheet. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments with lower credit risk.

Research and Development Expenses

Costs incurred in the research and development of new products are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, stock-based compensation, laboratory supplies, fees for professional service providers and costs associated with product development efforts, including preclinical studies and clinical trials. As of December 31, 2022 and 2021, respectively, the Company had $371,000 and $0 capitalized in property and equipment related to pre-production molds and tooling related to the Symphony device.

The Company estimates preclinical study and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.

Stock-Based Compensation

Share-based compensation expense for all share-based payment awards made to employees, directors and non-employees is measured based on the grant-date fair value of the award. Share-based compensation expense for awards granted to non-employees is determined using the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured.

The Company uses the Black-Scholes option pricing model to determine the fair value of options granted. The Company recognizes the compensation cost of share-based awards on a straight-line basis over the requisite service period. For stock awards for which vesting is subject to performance – based milestones, the expense is recorded over the implied service period after the point when the achievement of the milestone is probable, or the performance condition has been achieved.

The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The Company does not have a history of market prices of its common stock, and as such, volatility is estimated using historical volatilities of similar public entities. The expected life of the awards is estimated based on the simplified method for grants to employees and is based on the contractual term for non-employee awards. The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the awards. The dividend yield assumption is based on history and expectation of paying no dividends.

The Company recognizes forfeitures related to employee share-based payments when they occur. Forfeited share-based awards are recorded as a reduction to stock compensation expense.

Segment Reporting

Management has determined that the Company has one operating segment, which is consistent with the Company structure and how it manages the business.

Income Taxes

The Company follows accounting guidance regarding the recognition, measurement, presentation and disclosure of uncertain tax positions in the consolidated financial statements. Tax positions taken or expected to be taken in the course of preparing the Company’s tax returns are required to be evaluated to determine whether the tax positions are “more-likely-than-not” of being sustained by the applicable tax authorities. Tax positions not deemed to meet a more-likely-than-not threshold would be recorded in the consolidated financial statements. There are no uncertain tax positions that require accrual or disclosure as of December 31, 2022. Any interest or penalties are charged to expense. During the years ended December 31, 2022 and 2021, the Company had no significant interest and penalties. Tax years subsequent to December 31, 2018 are subject to examination by federal and state authorities.

The Company recognizes deferred tax assets and liabilities based on the impact of temporary differences between assets and liabilities recognized for tax and financial reporting purposes measured by applying enacted tax rates and laws that will be in effect when the differences are expected to reverse, net operating loss carryforwards and tax credits. Valuation allowances are provided when necessary to reduce net deferred tax assets to an amount that is more likely than not to be realized. The deferred tax benefit or expense for the period represents the change in the deferred tax asset or liability from the beginning to the end of the period.

Net Loss per Share

Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, convertible notes, options outstanding under the Company’s stock option plan and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.

Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):

	December 31
	2022		2021
Options to purchase common stock		719,835		503,433
Warrants for common stock		811,882		811,882
Class A Warrants for common stock		2,484,000		2,484,000
Class B Warrants for common stock		75,400		115,500

Recently Adopted Accounting Standards

In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases. The new guidance requires the recognition of lease liabilities, representing future minimum lease payments, on a discounted basis, and corresponding right-of-use assets on a balance sheet for most leases, along with requirements for enhanced disclosures to give financial statement users the ability to assess the amount, timing, and uncertainty of cash flows arising from leasing arrangements. The Company adopted the provisions of ASU 2016-02 on January 1, 2022 and elected to implement the transition package of practical expedients permitted within the new standard, which included (i) not reassessing whether expired or existing contract contain leases, (ii) not reassessing lease classification, and (iii) not revaluing initial direct costs for existing leases. Adoption of the new standard resulted in the recording of initial right-of-use assets and lease liabilities of approximately $200,000 as of January 1, 2022. The new standard did not materially impact the Company’s consolidated statements of operations or cash flows.

In May 2021, the FASB issued ASU 2021-04 Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early application is permitted, including in an interim period as of the beginning of the fiscal year that includes that interim period. The adoption date of this ASU did not have a material impact on the Company’s financial position and results of operations.

Recently Issued Accounting Standards

In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 805”), an amendment of the ASC. The amendments to ASU 805 address diversity and inconsistency related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination and require that an acquirer recognize and measure contract assets and contract liabilities acquired in accordance with ASC 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASC 606”). Under GAAP, an acquirer generally recognizes assets and liabilities assumed in a business combination, including contract assets and liabilities arising from revenue contracts with customers, at fair value on the acquisition date. ASU No. 2021-08 will result in the acquirer recording acquired contract assets and liabilities on the same basis that would have been recorded by the acquiree before the acquisition under ASC 606. This ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted, including adoption in an interim period. The Company is currently evaluating the effect that this standard may have on its financial position and related disclosures.

License and Supply Agreement with Toray Industries

12 Months Ended

Dec. 31, 2022

License and Supply Agreement with Toray Industries [Abstract]

LICENSE AND SUPPLY AGREEMENT WITH TORAY INDUSTRIES

3. LICENSE AND SUPPLY AGREEMENT WITH TORAY INDUSTRIES

On October 6, 2020, the Company entered into a License and Supply Agreement (“License Agreement”) with Toray Industries, Inc. (“Toray”). Under the License Agreement, the Company received the exclusive license (outside of Japan) to make and distribute protein detection cartridges that have a function of automatic stepwise feeding of reagent (the “Cartridges”). In exchange for the license, the Company committed to make two payments of $120,000 each, both of which were made in 2021. In addition, following the first sale of the Cartridges after regulatory approval, the Company will make royalty payments to Toray equal to 15% of the net sales of the Cartridges for the period that any underlying patents exist or five years after the first sale. Following the first sale after obtaining regulatory approval, the Company will make minimum annual royalty payments of $60,000 for the first year and $100,000 for each year thereafter, which shall be creditable against any royalties owed to Toray in such calendar year. There were no sales of or revenues from the Cartridges during the 12-month periods ended December 31, 2022 and 2021.

At December 31, 2022 and 2021, there were no amounts accrued related to the License Agreement.

Notes Payable

12 Months Ended

Dec. 31, 2022

Debt Disclosure [Abstract]

NOTES PAYABLE

4. NOTES PAYABLE

2017 Notes Payable

In 2017, the Company entered into multiple Unit Purchase Agreements (the “Financing”) whereby the Company issued 106 Units. Each Unit consisted of 100 shares of Series A redeemable, convertible preferred stock (“Series A”) at a purchase price of $100 per share and $10,000 in notes payable (the “Notes”). The Company defaulted on certain Notes issued in 2017 with aggregate principal amount of $1,060,000 in January 2021. On February 17, 2021, the Company repaid in cash $268,000 in principal and $2,010 in accrued interest on the Notes. On May 26, 2021, the remaining Notes of $580,000 were amended and restated (the “Amended Notes”). The Amended Notes accrue no interest and were due in May 2023. On June 8, 2021, the Amended Notes were automatically convertible into 580,000 shares of common stock at the conversion rate of $1.00 per share upon the issuance by the Company of securities to Sabby Volatility Warrant Master Fund, Ltd (“Sabby”) (the “Sabby Agreement”). The amendment and subsequent conversion of the Notes was accounted for as the debt settlement in equity under ASC 470-60 Troubled Debt Restructurings by Debtors. The Company recognized a gain on extinguishment of $6,360, equal to the difference between the carrying amount of the Amended Notes at the conversion date, totaling $586,360, and the fair value of the common stock shares issued to the noteholders of $580,000. This gain on extinguishment is included in other income on the consolidated statement of operations for the year ended December 31, 2021. For the year ended December 31, 2021 the interest expense on the Notes was $6,360.

The allocation of the gross proceeds from the Financing resulted in recording a premium on the Notes of $583,349. The premium is amortized over the term of the Notes. As a result of the event of default in January 2021 and the Notes becoming due on demand, the Company accelerated the amortization of the premium and discount and amortized the remaining balances during the three-month period ended March 31, 2021. The Company recognized the amortization of the premium of $145,837 as a reduction to non-cash interest expense during the year ended December 31, 2021. The premium amortization was included within interest income (expense) on the consolidated statements of operations.

In connection with the Financing, the Company paid $183,194 in issuance costs of which $91,597 was recorded as a discount on the Notes and is being amortized over the term of the Notes. The remaining $91,597 was netted with the proceeds allocated to Series A (see Note 7). The Company recognized the amortization of the discount of $22,899 as non-cash interest expense during the year ended December 31, 2021. The discount amortization was included in the interest income (expense) on the consolidated statements of operations.

2020 Subordinated Notes

On October 22, 2020, the Company issued $154,000 in subordinated promissory notes (“Subordinated Notes”) to the Company’s stockholders, including $30,000 to Lana Management and Business Research International, LLC (“LMBRI”). The Subordinated Notes accrued interest at 8% payable at each quarter end and had a maturity date of March 31, 2021. The Company defaulted on the Subordinated Notes on March 31, 2021, and the Subordinated Notes started to accrue 15% penalty interest starting on the date of default. For the year ended December 31, 2021 interest expense on the Subordinated Notes was $7,443. In conjunction with the issuance of the Subordinated Notes, the Company issued to each noteholder warrants to purchase shares of the Company’s common stock (“Subordinated Note Warrants”) totaling 4,846,688 Common Stock Warrants, of which 944,160 were issued to LMBRI. The allocation of the proceeds to the Subordinated Note Warrants resulted in a discount to the Subordinated Notes of $148,892. The Company amortized this discount through non-cash interest expense using the effective interest method, of which $83,752 was amortized during the year ended December 31, 2021, and included in the interest income (expense) in the consolidated statement of operations.

On June 7, 2021, the holders of $132,383 in principal of the Subordinated Notes elected to exercise their warrants into 4,166,357 shares of common stock, with the principal from the Subordinated Notes applied to the exercise price of the warrants. The remaining $21,617 principal amount of the Subordinated Notes was repaid in cash in 2021.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Convertible Debentures

12 Months Ended

Dec. 31, 2022

Convertible Debentures [Abstract]

CONVERTIBLE DEBENTURES

5. CONVERTIBLE DEBENTURES

On June 7, 2021, the Company entered into a Securities Purchase Agreement with Sabby, under which the Company committed to sell, and Sabby agreed to purchase, an aggregate of $4,500,000 principal amount of debentures, of which $3,000,000 upon execution of the agreement and the remaining $1,500,000 within three trading days of the later of (i) the date that the Company files the Registration Statement with the SEC and (ii) the date that the Company files the registration statement registering the shares of common stock to be issued in the IPO.

On June 8, 2021, the Company issued a total of $3,000,000 of 7.5% Senior Secured Convertible Debentures (the “Convertible Debentures”) to Sabby. On August 4, 2021, the Company issued an additional $1,500,000 of Convertible Debentures upon the filing of a registration statement in connection to the IPO, which was filed on July 22, 2021. The Convertible Debentures’ principal amount was convertible, at the holder’s option, into the Company’s Series D Convertible Preferred Stock (Series D) at $1,000 conversion price per share. The Convertible Debenture was automatically converted into Series D upon the effectiveness of an IPO. For the year ended December 31, 2021, interest expense on the Convertible Debentures was $124,829.

In connection with the IPO, all of the Company’s outstanding Convertible Debentures automatically converted into 4,500 shares of Series D Preferred Stock on the IPO Date. Subsequently, the holder of the 4,500 outstanding shares of Series D Preferred Stock exercised their option to convert their shares into 4,500,000 shares of common stock.

The Company incurred $729,658 in issuance costs consisting of cash payments and 225,000 warrants (the “Dawson Warrants”) issued to the placement agent for compensation for their services in relation to the issuance of the Convertible Debentures. The Dawson Warrants are exercisable after May 10, 2022 at the exercise price of $1.25 per share of common stock and have a 5-year term. The Dawson Warrants were accounted for as equity under ASC 815 – Derivatives and Hedging, and the grant date fair value was estimated to be $166,816 using Black-Scholes option pricing model and is included in issuance costs related to the Convertible Debentures.

The resulting discount is amortized over the term of the Convertible Debentures using the effective interest method. The Company recognized $266,193 of amortization of the discount during the year ended December 31, 2021, which was included within interest income (expense) in the consolidated statement of operations. The remaining $463,465 of unamortized discount was credited to the capital accounts at the time of conversion.

Warrants

12 Months Ended

Dec. 31, 2022

Warrants [Abstract]

WARRANTS

6. WARRANTS

The following table summarizes information with regard to warrants outstanding at December 31, 2022:

	Shares		Exercisable for	Weighted Average Exercise Price			Weighted Average Remaining Life (in Years)
Common Stock Warrants		811,882	Common Stock	$	3.24			3.1
Class A Warrants		2,484,000	Common Stock	$	7.00			3.8
Class B Warrants		75,400	Common Stock	$	10.00	¹		3.8

¹	Class B Warrants may also exercise such warrants on a “cashless” basis. See Class A Warrants and Class B Warrants subsection below.

No warrants were issued during the year ended December 31, 2022. The following assumptions were used in the Black-Scholes option pricing model to estimate the fair value of the warrants granted during the year ended December 31, 2021:

Risk-free interest rate			0.37% - 0.73%
Dividend rate			0%
Volatility			106.00% - 142.46%
Expected life (in years)			5

Common Stock Warrants

In March 2021, the Company granted a financial advisor warrants to purchase 226,599 shares of the Company’s common stock (the “Advisor Warrants”) as consideration for services in connection with the IPO. The warrants are exercisable at any time from the issuance date at the exercise price of $3.177 per share of common stock, subject to adjustment based on the amounts raised in the IPO, and have a 5-year term. These warrants were accounted for as equity and the grant date fair value was estimated to be $180,339 and were netted against the IPO proceeds. The terms of the advisory services agreement also provide for an incentive bonus of $200,000 payable upon closing of the IPO if such a closing occurs on or before January 31, 2022. This amount was netted against the IPO proceeds. As of December 31, 2022 and 2021, all of the Advisor Warrants remained outstanding.

In August 2021, the Company granted the Dawson Warrants to its placement agent for compensation for their services in relation to the issuance of the Convertible Debentures (see Note 5). As of December 31, 2022 and 2021, all of the Dawson Warrants remained outstanding.

In November 2021, the Company granted 108,000 warrants (the “Underwriter Warrants”) with an exercise price of $12.50, and a fair value of approximately $356,000, to the underwriter of the IPO which is in addition to the cash fees paid for underwriting the Company’s IPO. As of December 31, 2022 and 2021, all of the Underwriter Warrants remained outstanding.

In October 2020, in conjunction with the issuance of the Subordinated Notes, the Company granted 4,846,688 warrants (the “Subordinated Note Warrants”) to the noteholders, of which 944,160 were issued to LMBRI (see Note 4). In November 2021, the terms of some of the Subordinated Note Warrants were amended to provide for cashless exercise. During 2021, 4,718,251 of the Subordinated Note Warrants were exercised. As of December 31, 2022 and 2021, 128,438 of the Subordinated Note Warrants were outstanding.

Class A Warrants and Class B Warrants

In conjunction with the Company’s IPO as described in Note 1 the Company issued 2,160,000 Class A Warrants and 2,160,000 Class B Warrants. Additionally, the underwriter of the IPO exercised their overallotment option, solely with respect to the Class A Warrants and Class B Warrants, shortly after the IPO Date resulting in an additional issuance of 324,000 Class A Warrants and 324,000 Class B Warrants. From the net IPO proceeds, $5,164,751 and $7,323,161, respectively, were apportioned to the Class A Warrants and Class B Warrants.

Class A Warrants entitle the holder to purchase one share of common stock at an exercise price of $7.00 per share. As of December 31, 2022 and 2021 all Class A Warrants were outstanding.

Class B Warrants entitle the holder to purchase one share of common stock at an exercise price of $10.00 per share. Holders of Class B Warrants may also exercise such warrants on a “cashless” basis after the earlier of (i) 10 trading days from closing date of the offering or (ii) the time when $10.0 million of volume is traded in the Company’s common stock, if the volume weighted average price of the Company’s common stock on any trading day on or after the closing date of the offering fails to exceed the exercise price of the Class B Warrant (subject to adjustment as described in the warrant agreement). During 2022 and 2021, respectively, 40,100 and 2,368,500 Class B Warrants were exercised, all on a cashless basis. As of December 31, 2022 and 2021, respectively, 75,400 and 115,500 Class B Warrants were outstanding.

Warrants for Series B Redeemable, Convertible Preferred Stock

The 643 Series B Warrants (defined below) issued in conjunction with the Series B redeemable, convertible preferred stock (see Note 7) were accounted for as a derivative liability under ASC 480 – Distinguishing Liabilities from Equity. On June 1, 2021, the Series B Warrants were amended (“Amended Series B Warrants”) to become exercisable into 115,190 shares of common stock at an exercise price of $2.30 per share and are now reflected as common stock warrants in the table of outstanding warrants above. The Amended Series B Warrants were accounted for as equity and reclassified from liabilities into additional paid-in capital at the fair value determined as of the amendment date of $145,953.

The fair value of the outstanding the Amended Series B Warrants at June 1, 2021 was based on the assumptions as follows:

	June 1,
	2021
Risk-free interest rate		0.31% - 0.56%
Dividend rate		0%
Volatility		88.60%
Expected life (in years)		2.81– 4.22

Preferred Stock

12 Months Ended

Dec. 31, 2022

Stockholders' Equity Note [Abstract]

PREFERRED STOCK

7. PREFERRED STOCK

In 2017 in connection with the Financing (see Note 4), the Company issued 10,600 shares of Series A. The allocation of proceeds from the Financing was based on the relative fair values of the Notes and Series A resulting in the Series A being recorded at $476,651, net of $91,597 of issuance costs. Series A were being accreted to the redemption value through December 31, 2021, the redemption date. Accretion of Series A to redemption value, including the accretion of dividends and issuance costs, was $73,912 for year ended December 31, 2021.

In 2019, the Company entered into Subscription Agreements, as amended, for the issuance of 4,455 shares of Series B plus the committed future issuance of 415 of additional shares (the “Series B Financing”). The Series B Financing also resulted in the issuance of a total of 848 warrants (the “Series B Warrants”). Series B were subject to accretion to the redemption value through the redemption date. Accretion of Series B to redemption value, including the accretion of dividends and issuance costs, was $33,993 for the year ended December 31, 2021.

On November 19, 2020, the Company entered into a Subscription Agreement for the issuance of Series C redeemable, convertible preferred stock (the “Series C Financing”) with Toray. In connection with the Series C Financing, the Company issued 636 shares of Series C at a purchase price of $1,578.50 per share. Proceeds from the Series C Financing, net of issuance costs, were $994,832. Series C were being accreted to the redemption value through December 31, 2021, the redemption date. Accretion of Series C to redemption value, including the accretion of dividends and issuance costs, was $19,961 for the year December 31, 2021.

On June 1, 2021, in connection with the Sabby Agreement (see Note 5), Series A were converted into 1,668,016 shares of common stock, Series B were converted into 816,226 shares of common stock, and Series C were converted into 100,081 shares of common stock. The conversion was affected through the joint consent of the Company’s Board of Directors and stockholders and was subject to and in accordance with the terms of the Certificates of Designation. As a result of the conversion, the temporary equity balances at the conversion date were reclassified into the stockholders’ equity.

On June 7, 2021, the Company filed a certificate of designation of preferences, rights, and limitations with the state of Delaware for up to 4,500 shares of Series D convertible preferred stock (“Series D”). In connection with the IPO, all of the outstanding Convertible Debentures automatically converted into 4,500 shares of Series D on the IPO Date. In November 2021, all Series D was converted into 4,500,000 shares of common stock. There were no Series D outstanding as of December 31, 2022.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Stock Compensation

12 Months Ended

Dec. 31, 2022

Share-Based Payment Arrangement [Abstract]

STOCK COMPENSATION

8. STOCK COMPENSATION

Stock Incentive Plans

In 2018, the Company adopted the 2018 Stock Incentive Plan (the “2018 Plan”) for employees, consultants, and directors. The 2018 Plan, which is administered by the Company’s Board of Directors, permits the Company to grant incentive and nonqualified stock options for the purchase of common stock, and restricted stock awards. The maximum number of shares of common stock reserved for issuance under the 2018 Plan is 629,440. At December 31, 2022 there were 262,269 shares of common stock available for grant under the 2018 Plan.

On July 6, 2021, the Company’s Board of Directors and stockholders approved and adopted the Bluejay Diagnostics, Inc. 2021 Stock Plan (the “2021 Plan”). A total of 1,960,000 shares of common stock were approved to be initially reserved for issuance under the 2021 Stock Plan. At December 31, 2022 there were 1,339,721 shares of common stock available for grant under the 2021 Plan.

Stock Award Activity

The following table summarizes the status of the Company’s non-vested restricted stock awards for years ended December 31, 2022:

	Non-vested Restricted Stock Awards
	Number of Shares			Weighted Average Grant Date Fair Value
Outstanding at December 31, 2021		-		$	-
Granted		105,000			1.29
Vested		-			-
Forfeited		(45,000	)		1.29
Outstanding at December, 2022		60,000		$	1.29

The following is a summary of stock option activity for the year ended December 31, 2022:

	Number of Stock Options			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Outstanding at December 31, 2021		589,786		$	1.86		8.3	$	605,187
Granted		236,279			1.80
Exercised		(62,944	)		0.46				21,354
Cancelled and forfeited		(43,286	)		1.86
Outstanding at December 31, 2022		719,835		$	1.96		6.5	$	20,578
Exercisable at December 31, 2022		495,101		$	1.97		7.6	$	20,578

The weighted average grant date fair value of options granted during the years ended December 31, 2022 and 2021 was $1.42 per share and $1.16 per share, respectively. The Company calculated the grant-date fair value of stock option awards granted during the years ended December 31, 2022 and 2021 using the Black-Scholes model with the following assumptions:

	2022		2021
Risk-free interest rate		1.58% – 4.35%		0.78% – 1.27%
Expected dividend yield		0.00%		0.00%
Volatility factor		102.03% – 107.36%		106.00% – 114.76%
Expected life of option (in years)		5.40 – 6.00		5.00 – 6.00

Stock-Based Compensation Expense

For the years ended December 31, 2022 and 2021, the Company recorded stock-based compensation expense as follows:

	Year ended December 31,
	2022		2021
Research and development	$	64,352	$	29,543
General and administrative		367,702		17,315
Marketing and business development		950		21,600
Total stock-based compensation	$	433,004	$	68,458

At December 31, 2022, there was approximately $111,357 of unrecognized compensation expense related to non-vested stock option awards that are expected to be recognized over a weighted-average period of 2.2 years. At December 31, 2022, there was approximately $50,859 of unrecognized compensation expense related to non-vested restricted stock awards that are expected to be recognized over a weighted-average period of 2.1 years.

Related Party Transactions

12 Months Ended

Dec. 31, 2022

RELATED PARTY TRANSACTIONS

9. RELATED PARTY TRANSACTIONS

Lana Management and Business Research International, LLC

Lana Management and Business Research International, LLC (“LMBRI”) has board members in common with the Company. The Company and LMBRI entered into an Expense Sharing Agreement, whereby the Company will reimburse LMBRI monthly for certain shared expenses including insurance, rent, salaries, telephone, and other miscellaneous expenses. The Company was billed $4,000 monthly for these expenses through December 31, 2021. On January 1, 2022, the Company moved into its own leased facility and no longer shared expenses with LMBRI Such amounts are included in general and administrative expenses on the accompanying consolidated statements of operations. The Company also issued Subordinated Notes and Warrants to LMBRI in October 2020 as described in Note 4.

The table below summarizes the amounts incurred, paid, and balances due to LMBRI as of and for year’s ended December 31, 2022 and 2021.

	2022		2021
Expenses from LMBRI	$	-	$	48,000
Expense Sharing Agreement payments to LMBRI	$	-	$	171,102
Amounts payable to LMBRI	$	2,000	$	2,000
Interest Incurred and Payments on Subordinated Notes to LMBRI (Note 4)	$	-	$	3,303

NanoHybrids, LLC

In December 2021, the Company entered into an agreement with NanoHybrids, LLC (“NanoHybrids”) to utilize the Company’s research and development staff and laboratory facility when available to perform work for NanoHybrids. Any hours worked by Company employees for NanoHybrids is billed to NanoHybrids at a bill rate of the respective employee’s fully burdened personnel cost plus 10%. NanoHybrids is wholly owned by the Company’s Chief Technology Officer. The table below summarizes the amounts earned and due from NanoHybrids for the years ended December 31, 2022 and 2021 and balances due as of December 31, 2022 and 2021:

	Year Ended December 31,
	2022		2021
Income from NanoHybrids included in Other Income	$	163,256	$	-
Cash receipts from NanoHybrids	$	143,525	$	-

	As of December 31,
	2022		2021
Amounts receivable from NanoHybrids included in Prepaids and Other Current Assets	$	19,731	$	-

Toray Industries, Inc.

In June 2022, the Company sold five Symphony analyzers to the Company’s business partner, Toray, for $249,040, all of which was paid in June 2022. Future sales to Toray are not currently anticipated.

Supplemental Balance Sheet Information

12 Months Ended

Dec. 31, 2022

Supplemental Balance Sheet Information [Abstract]

SUPPLEMENTAL BALANCE SHEET INFORMATION

10. SUPPLEMENTAL BALANCE SHEET INFORMATION

Prepaid expenses and other current assets consist of the following:

	December 31, 2022		December 31, 2021
Prepaid insurance	$	751,979	$	1,127,062
Prepaid clinical trial expenses		-		160,467
Vendor prepayments		681,218		160,000
Prepaid other		240,283		165,179
Total prepaid expenses and other current assets	$	1,673,480	$	1,612,708

Accrued expenses and other current liabilities consist of the following:

	December 31, 2022		December 31, 2021
Accrued personnel costs	$	533,577	$	157,938
Accrued other		302,153		181,446
Total accrued expenses and other current liabilities	$	835,730	$	339,384

Property and Equipment

12 Months Ended

Dec. 31, 2022

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

11. PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at December 31, 2022 and 2021:

		December 31,
	Depreciable lives	2022			2021
Construction in process		$	375,466		$	15,078
Furniture, fixtures, and equipment	3-5 years		136,942			24,915
Software	3 years		4,457			4,619
Lab equipment	3-5 years		1,268,380			741,591
Leasehold improvements	Life of lease		43,231			-
			1,828,476			786,203
Less: accumulated depreciation			(596,406	)		(448,837	)
Property and equipment, net		$	1,232,070		$	337,366

Leases

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

LEASES

12. LEASES

The Company primarily enters into lease arrangements for office and laboratory space. A summary of supplemental lease information is as follows:

	Year ended December 31, 2022
Weighted average remaining lease term – operating leases (in years)		3.7
Weighted average remaining lease term – finance leases (in years)		5.1
Weighted average discount rate		7.0	%
Operating cash flows from operating leases	$	149,770

A summary of the Company’s lease assets and liabilities are as follows:

	December 31, 2022
Operating lease right-of-use asset	$	465,514
Finance lease asset included in property & equipment, net		21,067
Total lease assets		486,581
Current portion of operating lease liability		168,706
Current portion of finance lease liability included in accrued expenses		4,807
Non-current operating lease liabilities		323,915
Non-current finance lease liabilities included in other non-current liabilities		15,823
Total lease liabilities	$	513,251

A summary of the Company’s estimated operating lease payments are as follows:

Year
2023	$	168,706
2024		162,991
2025		100,000
2026		100,000
2027		25,000
Thereafter		-
Total future lease payments		556,697
Less: Imputed interest		64,076
Present value of lease liability	$	492,621

Commitments and Contingencies

12 Months Ended

Dec. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

13. COMMITMENTS AND CONTINGENCIES

Purchase Commitments

In October 2022, the Company entered into a non-cancelable purchase commitment with an international materials vendor for items needed for both development of the Symphony product line and also to resell to its customers. This agreement commits the Company to purchase approximately $800,000 in goods, of which 50% was prepaid in 2022. No goods have been received under this arrangement as of December 31, 2022.

The Company had multiple open purchase commitments with its primary contract manufacturing organization in Japan related to the buildout of a manufacturing line for the IL-6 cartridges for the Symphony device. As of December 31, 2022, the total open non-cancellable commitments for the manufacturing line buildout totaled approximately $375,000.

As of December 31, 2022, the Company has entered into other non-cancelable purchase commitments primarily for R&D supplies and key advisory services. The purchase commitments covered by these agreements are for less than one year and aggregate to approximately $700,000.

Minimum Royalties

As required under the License Agreement (see Note 3), following the first sale of Cartridges, the Company will also make royalty payments to Toray equal to 15% of the net sales of the Cartridges for the period that any underlying patents exist or for 5 years after the first sale. Following the first sale, the Company will pay a one-time minimum royalty of $60,000, which shall be creditable against any royalties owed to Toray in such calendar year. The Company will pay a minimum royalty of $100,000 in each year thereafter, which are creditable against any royalties owed to Toray in such calendar year. There were no sales of or revenues from the Cartridges through December 31, 2022.

Indemnification

The Company has certain agreements with service providers with which it does business that contain indemnification provisions pursuant to which the Company typically agrees to indemnify the party against certain types of third-party claims. The Company accrues for known indemnification issues when a loss is probable and can be reasonably estimated. The Company would also accrue for estimated incurred but unidentified indemnification issues based on historical activity. As the Company has not incurred any indemnification losses to date, there were no accruals for or expenses related to indemnification issues for any period presented.

Income Tax

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

INCOME TAX

14. INCOME TAX

No provision for federal income taxes has been recorded for the years ended December 31, 2022 and 2021 due to net losses and the valuation allowance established.

Significant components of the Company’s deferred tax assets are as follows:

	As of December 31,
	2022			2021
Deferred tax assets:
Net operating losses	$	3,043,585		$	1,791,043
Tax credits		190,489			3,659
Intangible assets		66,716			68,564
Capitalized R&D expenses		1,018,165			-
Fixed assets		37,580			-
Other		272,106			97,945
Total deferred tax assets		4,628,641			1,961,211
Valuation allowance		(4,628,641	)		(1,934,351	)
Net deferred tax assets	$	-		$	26,860
Deferred tax liabilities:
Fixed assets		-			(26,860	)
Net deferred tax assets	$	-		$	(26,860	)

A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 2022 and 2021 is as follows:

	Year Ended December 31,
	2022			2021
Federal statutory rate		21.00	%		21.00	%
State income taxes, net of federal benefit and tax credits		6.86	%		5.41	%
Change in valuation allowance		(29.06	)%		(25.88	)%
Permanent differences		1.20	%		(0.53	)%
Effective tax rate		0.00	%		0.00	%

The Company regularly assesses the need for a valuation allowance against its deferred tax assets. In making that assessment, the Company considers both positive and negative evidence related to the likelihood of realization of the deferred tax assets to determine, based on the weight of available evidence, whether it is more-likely-than-not that some or all of the deferred tax assets will not be realized. In assessing the realizability of deferred tax assets, the Company considers taxable income in prior carryback years, as permitted under the tax law, forecasted taxable earnings, tax planning strategies, and the expected timing of the reversal of temporary differences. This determination requires significant judgment, including assumptions about future taxable income that are based on historical and projected information and is performed on a jurisdiction-by-jurisdiction basis.

The Company continues to maintain a full valuation allowance against its net deferred tax assets. During the years ended December 31, 2022 and 2021, management assessed the positive and negative evidence in its operations and concluded that it is more likely than not that its deferred tax assets as of December 31, 2022 and 2021 will not be realized given the Company’s history of operating losses. The valuation allowance against deferred tax assets increased by approximately $2.7 million and $900,000 and during 2022 and 2021, respectively, related mainly to a full valuation allowance recorded against capitalized research expenditures, additional net operating losses and tax credits generated in the year.

At December 31, 2022, the Company had federal net operating loss carryforwards of approximately $11.2 million. The Company’s federal net operating losses incurred prior to 2018 totaling $713,000 expire through 2037, while its federal net operating losses incurred in 2018 to 2022 totaling $10.5 million can be carried forward indefinitely.

As of December 31, 2022, the Company had post-apportioned state net operating losses of $10.9 million that can generally be carried forward 20 years and will expire at various dates through 2042. As of December 31, 2021, the Company had post-apportioned Massachusetts net operating losses of $6.3 million that can generally be carried forward 20 years and will expire at various dates through 2041.

The Tax Cuts and Jobs Act resulted in significant changes to the treatment of research or experimental (“R&E”) expenditures under Section 174. For tax years beginning after December 31, 2021, taxpayers are required to capitalize and amortize all R&E expenditures that are paid or incurred in connection with their trade or business which represent costs in the experimental or laboratory sense. Specifically, costs for U.S. based R&E activities must be amortized over five years and costs for foreign R&E activities must be amortized over 15 years; both using a midyear convention. The Company has implemented this standard on January 1, 2022, noting that the impact on the Company’s consolidated financial statements was immaterial.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Accounting Policies, by Policy (Policies)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Use of estimates

Use of Estimates

Financial Statement Reclassifications

Financial Statement Reclassifications

Certain balances in the prior year consolidated financial statements have been reclassified to conform to the presentation in the current year consolidated financial statements.

Cash and Cash Equivalents

Cash and Cash Equivalents

Revenue Recognition

Revenue Recognition

Leases

Leases

Finance leases are not material to the Company’s consolidated financial statements.

Concentration of Credit Risk

Concentration of Credit Risk

Research and development expenses

Research and Development Expenses

Stock-based compensation

Stock-Based Compensation

The Company recognizes forfeitures related to employee share-based payments when they occur. Forfeited share-based awards are recorded as a reduction to stock compensation expense.

Segment Reporting

Segment Reporting

Management has determined that the Company has one operating segment, which is consistent with the Company structure and how it manages the business.

Income Taxes

Income Taxes

Net Loss per Share

Net Loss per Share

Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):

	December 31
	2022		2021
Options to purchase common stock		719,835		503,433
Warrants for common stock		811,882		811,882
Class A Warrants for common stock		2,484,000		2,484,000
Class B Warrants for common stock		75,400		115,500

Recently Adopted Accounting Standards

Recently Adopted Accounting Standards

Recently Issued Accounting Standards

Recently Issued Accounting Standards

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Schedule of diluted net loss per share

	December 31
	2022		2021
Options to purchase common stock		719,835		503,433
Warrants for common stock		811,882		811,882
Class A Warrants for common stock		2,484,000		2,484,000
Class B Warrants for common stock		75,400		115,500

Warrants (Tables)

12 Months Ended

Dec. 31, 2022

Warrants (Tables) [Line Items]

Schedule of information with regard to warrants outstanding

	Shares		Exercisable for	Weighted Average Exercise Price			Weighted Average Remaining Life (in Years)
Common Stock Warrants		811,882	Common Stock	$	3.24			3.1
Class A Warrants		2,484,000	Common Stock	$	7.00			3.8
Class B Warrants		75,400	Common Stock	$	10.00	¹		3.8

¹	Class B Warrants may also exercise such warrants on a “cashless” basis. See Class A Warrants and Class B Warrants subsection below.

Schedule of fair value of the warrants granted

	June 1,
	2021
Risk-free interest rate		0.31% - 0.56%
Dividend rate		0%
Volatility		88.60%
Expected life (in years)		2.81– 4.22

Black Scholes Option Pricing Model [Member]

Warrants (Tables) [Line Items]

Schedule of fair value of the warrants granted

Risk-free interest rate			0.37% - 0.73%
Dividend rate			0%
Volatility			106.00% - 142.46%
Expected life (in years)			5

Stock Compensation (Tables)

12 Months Ended

Dec. 31, 2022

Share-Based Payment Arrangement [Abstract]

Schedule of non-vested restricted stock awards

	Non-vested Restricted Stock Awards
	Number of Shares			Weighted Average Grant Date Fair Value
Outstanding at December 31, 2021		-		$	-
Granted		105,000			1.29
Vested		-			-
Forfeited		(45,000	)		1.29
Outstanding at December, 2022		60,000		$	1.29

Schedule of stock option activity

	Number of Stock Options			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Outstanding at December 31, 2021		589,786		$	1.86		8.3	$	605,187
Granted		236,279			1.80
Exercised		(62,944	)		0.46				21,354
Cancelled and forfeited		(43,286	)		1.86
Outstanding at December 31, 2022		719,835		$	1.96		6.5	$	20,578
Exercisable at December 31, 2022		495,101		$	1.97		7.6	$	20,578

Schedule of grant-date fair value of share-based awards granted

	2022		2021
Risk-free interest rate		1.58% – 4.35%		0.78% – 1.27%
Expected dividend yield		0.00%		0.00%
Volatility factor		102.03% – 107.36%		106.00% – 114.76%
Expected life of option (in years)		5.40 – 6.00		5.00 – 6.00

Schedule of stock-based compensation expense

	Year ended December 31,
	2022		2021
Research and development	$	64,352	$	29,543
General and administrative		367,702		17,315
Marketing and business development		950		21,600
Total stock-based compensation	$	433,004	$	68,458

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2022

Schedule of summarizes the amounts incurred

	2022		2021
Expenses from LMBRI	$	-	$	48,000
Expense Sharing Agreement payments to LMBRI	$	-	$	171,102
Amounts payable to LMBRI	$	2,000	$	2,000
Interest Incurred and Payments on Subordinated Notes to LMBRI (Note 4)	$	-	$	3,303

Schedule of summarizes the amounts incurred

	Year Ended December 31,
	2022		2021
Income from NanoHybrids included in Other Income	$	163,256	$	-
Cash receipts from NanoHybrids	$	143,525	$	-

	As of December 31,
	2022		2021
Amounts receivable from NanoHybrids included in Prepaids and Other Current Assets	$	19,731	$	-

Supplemental Balance Sheet Information (Tables)

12 Months Ended

Dec. 31, 2022

Supplemental Balance Sheet Information [Abstract]

Schedule of prepaid expenses and other current assets

	December 31, 2022		December 31, 2021
Prepaid insurance	$	751,979	$	1,127,062
Prepaid clinical trial expenses		-		160,467
Vendor prepayments		681,218		160,000
Prepaid other		240,283		165,179
Total prepaid expenses and other current assets	$	1,673,480	$	1,612,708

Schedule of accrued expenses and other current liabilities

	December 31, 2022		December 31, 2021
Accrued personnel costs	$	533,577	$	157,938
Accrued other		302,153		181,446
Total accrued expenses and other current liabilities	$	835,730	$	339,384

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2022

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

		December 31,
	Depreciable lives	2022			2021
Construction in process		$	375,466		$	15,078
Furniture, fixtures, and equipment	3-5 years		136,942			24,915
Software	3 years		4,457			4,619
Lab equipment	3-5 years		1,268,380			741,591
Leasehold improvements	Life of lease		43,231			-
			1,828,476			786,203
Less: accumulated depreciation			(596,406	)		(448,837	)
Property and equipment, net		$	1,232,070		$	337,366

Leases (Tables)

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Schedule of lease arrangements for office and laboratory space

	Year ended December 31, 2022
Weighted average remaining lease term – operating leases (in years)		3.7
Weighted average remaining lease term – finance leases (in years)		5.1
Weighted average discount rate		7.0	%
Operating cash flows from operating leases	$	149,770

Schedule of lease assets and liabilities

	December 31, 2022
Operating lease right-of-use asset	$	465,514
Finance lease asset included in property & equipment, net		21,067
Total lease assets		486,581
Current portion of operating lease liability		168,706
Current portion of finance lease liability included in accrued expenses		4,807
Non-current operating lease liabilities		323,915
Non-current finance lease liabilities included in other non-current liabilities		15,823
Total lease liabilities	$	513,251

Schedule of estimated lease payments

Year
2023	$	168,706
2024		162,991
2025		100,000
2026		100,000
2027		25,000
Thereafter		-
Total future lease payments		556,697
Less: Imputed interest		64,076
Present value of lease liability	$	492,621

Income Tax (Tables)

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Schedule of company’s deferred tax assets

	As of December 31,
	2022			2021
Deferred tax assets:
Net operating losses	$	3,043,585		$	1,791,043
Tax credits		190,489			3,659
Intangible assets		66,716			68,564
Capitalized R&D expenses		1,018,165			-
Fixed assets		37,580			-
Other		272,106			97,945
Total deferred tax assets		4,628,641			1,961,211
Valuation allowance		(4,628,641	)		(1,934,351	)
Net deferred tax assets	$	-		$	26,860
Deferred tax liabilities:
Fixed assets		-			(26,860	)
Net deferred tax assets	$	-		$	(26,860	)

Schedule of statutory tax rates and the effective tax rates

	Year Ended December 31,
	2022			2021
Federal statutory rate		21.00	%		21.00	%
State income taxes, net of federal benefit and tax credits		6.86	%		5.41	%
Change in valuation allowance		(29.06	)%		(25.88	)%
Permanent differences		1.20	%		(0.53	)%
Effective tax rate		0.00	%		0.00	%

Nature of Operations and Basis of Presentation (Details) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares
Accounting Policies [Abstract]
Initial public offering description	The Company completed its initial public offering (the “IPO”) in November 2021 (“IPO Date”), whereby it sold 2,160,000 Units at a price of $10.00, with each Unit consisting of one share of the Company’s common stock, one warrant to purchase one share of common stock at an exercise price of $7.00 per share (“Class A Warrant”), and one warrant to purchase one share of common stock at an exercise price of $10.00 (“Class B Warrant”) (collectively, a “Unit”). Each warrant contained within the Units is exercisable until the fifth anniversary of the IPO Date, however, holders of Class B Warrants may exercise such warrants on a “cashless” basis after the earlier of (i) 10 trading days from closing date of the offering or (ii) the time when $10.0 million of volume is traded in the Company’s common stock, if the volume weighted average price of the Company’s common stock on any trading day on or after the closing date of the offering fails to exceed the exercise price of the Class B Warrant (subject to adjustment as described in the warrant agreement). Additionally, the underwriter of the IPO exercised their overallotment option, solely with respect to the Class A Warrants and Class B Warrants, shortly after the IPO Date which resulted in an additional issuance of 324,000 Class A Warrants and 324,000 Class B Warrants. The gross proceeds from the IPO were approximately $21.6 million and were offset by $2.8 million in offering costs.
Common stock per share (in Dollars per share) \| $ / shares	$ 1
Cash and cash equivalents.	$ 10.1
Accounts payable and accrued expenses	1.6
Capital commitments	$ 2.0

Summary of Significant Accounting Policies (Details) - USD ($)	Jun. 07, 2021	Dec. 31, 2022	Jan. 01, 2022	Dec. 31, 2021
Summary of Significant Accounting Policies (Details) [Line Items]
Stock dividend (in Shares)	2.15
Capitalized in property and equipment		$ 1,828,476		$ 786,203
Capitalized in property and equipment				$ 0
Right-of use assets and lease liabilities			$ 200,000
Construction in Progress [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Capitalized in property and equipment		$ 371,000

Summary of Significant Accounting Policies (Details) - Schedule of diluted net loss per share - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Diluted Net Loss Per Share [Abstract]
Options to purchase common stock	$ 719,835	$ 503,433
Warrants for common stock	811,882	811,882
Class A warrants for common stock	2,484,000	2,484,000
Class B Warrants for common stock	$ 75,400	$ 115,500

License and Supply Agreement with Toray Industries (Details) - USD ($)		12 Months Ended
	Oct. 06, 2020	Dec. 31, 2022
License and Supply Agreement with Toray Industries (Details) [Line Items]
Percentage of royalty payments	15.00%
Sale term	5 years
Maximum [Member]
License and Supply Agreement with Toray Industries (Details) [Line Items]
Annual royalty payments		$ 100,000
Toray Agreement [Member]
License and Supply Agreement with Toray Industries (Details) [Line Items]
Payments	$ 120,000
Minimum [Member]
License and Supply Agreement with Toray Industries (Details) [Line Items]
Annual royalty payments		$ 60,000

Notes Payable (Details) - USD ($)		1 Months Ended	12 Months Ended
Notes Payable (Details) - USD ($)	Jun. 08, 2021	Oct. 22, 2020	Dec. 31, 2022	Dec. 31, 2021	Jun. 07, 2021	May 26, 2021	Feb. 17, 2021	Jan. 31, 2021
Notes Payable (Details) [Line Items]
Issued units (in Shares)			106
Unit purchase agreements			Each Unit consisted of 100 shares of Series A redeemable, convertible preferred stock (“Series A”) at a purchase price of $100 per share and $10,000 in notes payable (the “Notes”).
Aggregate principal amount					$ 132,383			$ 1,060,000
Cash repaid							$ 268,000
Accrued interest							$ 2,010
Remaining notes						$ 580,000
Common stock, conversion rate (in Dollars per share)	$ 1
Gain on extinguishment of debt			$ 6,360
Conversion amount			580,000
Interest expense				$ 6,360
Gross proceeds from the financing			583,349
Amortization of the discount			145,837	22,899
Issuance cost			183,194
Discount notes			$ 91,597
Subordinated promissory notes issued		$ 154,000
Subordinated notes, accrued interest		8.00%
Subordinated notes, penalty interest		15.00%
Interest expense				7,443
Common stock warrants issued (in Shares)			4,846,688
Shares of common stock					$ 4,166,357
Principal amount				$ 21,617
Common Stock [Member]
Notes Payable (Details) [Line Items]
Conversion shares of common stock (in Shares)	580,000			7,084,323
Subordinated Debt [Member]
Notes Payable (Details) [Line Items]
Subordinated notes issued			$ 148,892
Series A Preferred Stock [Member]
Notes Payable (Details) [Line Items]
Remaining proceeds			91,597
2020 Subordinated Notes [Member]
Notes Payable (Details) [Line Items]
Amortization of the discount			$ 83,752
LMBRI [Member]
Notes Payable (Details) [Line Items]
Company’s stockholders		$ 30,000
Shares issued (in Shares)			944,160
Convertible Debt [Member]
Notes Payable (Details) [Line Items]
Conversion amount			$ 586,360

Convertible Debentures (Details) - USD ($)			12 Months Ended
Convertible Debentures (Details) - USD ($)	May 10, 2022	Jun. 08, 2021	Dec. 31, 2022	Aug. 04, 2021	Jun. 07, 2021
Convertible Debentures (Details) [Line Items]
Debt issued					$ 4,500,000
Execution agreement amount					3,000,000
Remaining amount					$ 1,500,000
Issuance of convertible debenture		$ 3,000,000
Senior secured convertible debentures percentage		7.50%
Additional convertible debentures				$ 1,500,000
Interest expense on convertible debentures			$ 124,829
Exercise price per share (in Dollars per share)	$ 1.25
Common stock term	5 years
Fair value estimated			166,816
Recognized amortization			266,193
Unamortized discount			463,465
Dawson Warrants [Member]
Convertible Debentures (Details) [Line Items]
Issuance cost			$ 729,658
Warrants issued (in Shares)			225,000
Series D Preferred Stock [Member]
Convertible Debentures (Details) [Line Items]
Conversion price per share (in Dollars per share)			$ 1,000
Series D Preferred Stock [Member] \| IPO [Member]
Convertible Debentures (Details) [Line Items]
Convertible debentures description			In connection with the IPO, all of the Company’s outstanding Convertible Debentures automatically converted into 4,500 shares of Series D Preferred Stock on the IPO Date. Subsequently, the holder of the 4,500 outstanding shares of Series D Preferred Stock exercised their option to convert their shares into 4,500,000 shares of common stock.

Warrants (Details) - USD ($)			12 Months Ended
Warrants (Details) - USD ($)	Jan. 31, 2022	Jun. 01, 2021	Dec. 31, 2022	Dec. 31, 2021	Nov. 30, 2021	Mar. 31, 2021	Oct. 31, 2020
Warrants (Details) [Line Items]
Warrant to purchase shares						226,599
Issuance exercise price, per share (in Dollars per share)		$ 2.3	$ 3.177
Warrant term			5 years
Initial public offering proceeds (in Dollars)			$ 180,339
Payable amount (in Dollars)	$ 200,000
Warrants granted					108,000		944,160
Fair value amount (in Dollars)					$ 356,000
Warrants exercised				4,718,251
Warrants outstanding			128,438	128,438
Class B Warrant rights, description			Holders of Class B Warrants may also exercise such warrants on a “cashless” basis after the earlier of (i) 10 trading days from closing date of the offering or (ii) the time when $10.0 million of volume is traded in the Company’s common stock, if the volume weighted average price of the Company’s common stock on any trading day on or after the closing date of the offering fails to exceed the exercise price of the Class B Warrant (subject to adjustment as described in the warrant agreement).
Subordinated Note Warrants [Member]
Warrants (Details) [Line Items]
Warrants granted							4,846,688
Class B Warrants [Member]
Warrants (Details) [Line Items]
Warrant to purchase shares			1
Issuance exercise price, per share (in Dollars per share)			$ 10		$ 12.5
Warrants granted			2,160,000
Warrants exercised			40,100	2,368,500
Warrants outstanding			75,400	115,500
Additional issuance of warrants			324,000
Class A Warrants [Member]
Warrants (Details) [Line Items]
Warrant to purchase shares			1
Issuance exercise price, per share (in Dollars per share)			$ 7
Warrants granted			2,160,000
Additional issuance of warrants			324,000
Series B Warrants [Member]
Warrants (Details) [Line Items]
Common stock exercisable shares		115,190
Fair value of warrants (in Dollars)		$ 145,953
Class A Warrants [Member]
Warrants (Details) [Line Items]
Initial public offering proceeds (in Dollars)			$ 5,164,751
Class B Warrants [Member]
Warrants (Details) [Line Items]
Initial public offering proceeds (in Dollars)			$ 7,323,161

Warrants (Details) - Schedule of information with regard to warrants outstanding

12 Months Ended

Dec. 31, 2022

$ / shares

Common Stock Warrants [Member]

Class of Warrant or Right [Line Items]

Shares | shares

811,882

Exercisable for

Common Stock

Weighted Average Exercise Price | $ / shares

$ 3.24

Weighted Average Remaining Life (in Years)

3 years 1 month 6 days

Class A Warrants [Member]

Class of Warrant or Right [Line Items]

Shares | shares

2,484,000

Exercisable for

Common Stock

Weighted Average Exercise Price | $ / shares

$ 7

Weighted Average Remaining Life (in Years)

3 years 9 months 18 days

Class B Warrants [Member]

Class of Warrant or Right [Line Items]

Shares | shares

75,400

Exercisable for

Common Stock

Weighted Average Exercise Price | $ / shares

$ 10

^[1]

Weighted Average Remaining Life (in Years)

3 years 9 months 18 days

[1]	Class B Warrants may also exercise such warrants on a “cashless” basis. See Class A Warrants and Class B Warrants subsection below.

Warrants (Details) - Schedule of fair value of the warrants granted - Black Scholes Option Pricing Model [Member]	12 Months Ended
	Dec. 31, 2021
Warrants (Details) - Schedule of fair value of the warrants granted [Line Items]
Dividend rate	0.00%
Expected life (in years)	5 years
Minimum [Member]
Warrants (Details) - Schedule of fair value of the warrants granted [Line Items]
Risk-free interest rate	0.37%
Volatility	106.00%
Maximum [Member]
Warrants (Details) - Schedule of fair value of the warrants granted [Line Items]
Risk-free interest rate	0.73%
Volatility	142.46%

Warrants (Details) - Schedule of fair value of the warrants granted - Preferred stock outstanding - Warrant [Member]	1 Months Ended
	Jun. 30, 2021
Warrants (Details) - Schedule of fair value of the warrants granted [Line Items]
Dividend rate	0.00%
Volatility	88.60%
Minimum [Member]
Warrants (Details) - Schedule of fair value of the warrants granted [Line Items]
Risk-free interest rate	0.31%
Expected life (in years)	2 years 9 months 21 days
Maximum [Member]
Warrants (Details) - Schedule of fair value of the warrants granted [Line Items]
Risk-free interest rate	0.56%
Expected life (in years)	4 years 2 months 19 days

Preferred Stock (Details) - USD ($)	1 Months Ended			12 Months Ended
Preferred Stock (Details) - USD ($)	Nov. 30, 2021	Nov. 19, 2021	Dec. 31, 2017	Dec. 31, 2021	Dec. 31, 2019	Jun. 07, 2021	Jun. 01, 2021
Preferred Stock (Details) [Line Items]
Issuance cost					4,455
Proceeds from financing costs (in Dollars)			$ 476,651
Dividends and issuance costs (in Dollars)			$ 91,597
Accretion of dividends and issuance costs (in Dollars)				$ 73,912
Issuance of warrants shares					848
Series A Preferred Stock [Member]
Preferred Stock (Details) [Line Items]
Issuance cost			10,600
Converted shares							1,668,016
Series B Preferred Stock [Member]
Preferred Stock (Details) [Line Items]
Accretion of dividends and issuance costs (in Dollars)				33,993
Additional shares					415
Converted shares							816,226
Series C Preferred Stock [Member]
Preferred Stock (Details) [Line Items]
Issuance cost		636
Shares issued price per share (in Dollars per share)		$ 1,578.5
Net of issuance costs (in Dollars)		$ 994,832
Dividends and issuance costs (in Dollars)				$ 19,961
Converted shares							100,081
Series D Preferred Stock [Member]
Preferred Stock (Details) [Line Items]
Convertible shares						4,500
Converted shares of common stock	4,500,000
Series D Preferred Stock [Member] \| IPO [Member]
Preferred Stock (Details) [Line Items]
Converted shares						4,500

Stock Compensation (Details) - USD ($)	12 Months Ended
Stock Compensation (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Stock Compensation (Details) [Line Items]
Weighted average grant date fair value of options granted (in Dollars per share)	$ 1.42	$ 1.16
Unrecognized compensation expense (in Dollars)	$ 50,859
Weighted-average period	2 years 1 month 6 days
2018 Stock Incentive Plan [Member]
Stock Compensation (Details) [Line Items]
Shares reserved for issuance	629,440
Shares available for grants	262,269
2021 Plan [Member]
Stock Compensation (Details) [Line Items]
Shares reserved for issuance	1,960,000
Shares available for grants	1,339,721
Non-vested stock option [Member]
Stock Compensation (Details) [Line Items]
Unrecognized compensation expense (in Dollars)	$ 111,357
Weighted-average period	2 years 2 months 12 days

Stock Compensation (Details) - Schedule of non-vested restricted stock awards	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Schedule of Non Vested Restricted Stock Awards [Abstract]
Number of Shares, Outstanding at beginning balance \| shares
Weighted Average Grant Date Fair Value, Outstanding at beginning balance \| $ / shares
Number of Shares, Granted \| shares	105,000
Weighted Average Grant Date Fair Value, Granted \| $ / shares	$ 1.29
Number of Shares, Vested \| shares
Weighted Average Grant Date Fair Value, Vested \| $ / shares
Number of Shares, Forfeited \| shares	(45,000)
Weighted Average Grant Date Fair Value, Forfeited \| $ / shares	$ 1.29
Number of Shares, Outstanding at ending balance \| shares	60,000
Weighted Average Grant Date Fair Value, Outstanding at ending balance \| $ / shares	$ 1.29

Stock Compensation (Details) - Schedule of stock option activity	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Schedule of Stock Option Activity [Abstract]
Number of Stock Options, Outstanding at beginning balance	589,786
Weighted Average Exercise Price Per Share, Outstanding at beginning balance (in Dollars per share) \| $ / shares	$ 1.86
Weighted Average Remaining Contractual Life in Years, Outstanding at beginning balance	8 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding at beginning balance (in Dollars) \| $	$ 605,187
Number of Stock Options, Outstanding at ending balance	719,835
Weighted Average Exercise Price Per Share, Outstanding at ending balance (in Dollars per share) \| $ / shares	$ 1.96
Weighted Average Remaining Contractual Life in Years, Outstanding at ending balance	6 years 6 months
Aggregate Intrinsic Value, Outstanding at ending balance (in Dollars) \| $	$ 20,578
Number of Stock Options, Exercisable \| shares	495,101
Weighted Average Exercise Price Per Share, Exercisable (in Dollars per share) \| $ / shares	$ 1.97
Weighted Average Remaining Contractual Life in Years, Exercisable	7 years 7 months 6 days
Aggregate Intrinsic Value, Exercisable (in Dollars) \| $	$ 20,578
Number of Stock Options, Granted	236,279
Weighted Average Exercise Price Per Share, Granted (in Dollars per share) \| $ / shares	$ 1.8
Number of Stock Options, Exercised	(62,944)
Weighted Average Exercise Price Per Share, Exercised	0.46
Aggregate Intrinsic value, Exercised	21,354
Number of Stock Options, Cancelled and forfeited	(43,286)
Weighted Average Exercise Price Per Share, Cancelled and forfeited (in Dollars per share) \| $ / shares	$ 1.86

Stock Compensation (Details) - Schedule of grant-date fair value of share-based awards granted	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Stock Compensation (Details) - Schedule of grant-date fair value of share-based awards granted [Line Items]
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Stock Compensation (Details) - Schedule of grant-date fair value of share-based awards granted [Line Items]
Risk-free interest rate	1.58%	0.78%
Volatility factor	102.03%	106.00%
Expected life of option (in years)	5 years 4 months 24 days	5 years
Maximum [Member]
Stock Compensation (Details) - Schedule of grant-date fair value of share-based awards granted [Line Items]
Risk-free interest rate	4.35%	1.27%
Volatility factor	107.36%	114.76%
Expected life of option (in years)	6 years	6 years

Stock Compensation (Details) - Schedule of stock-based compensation expense - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Stock Compensation (Details) - Schedule of stock-based compensation expense [Line Items]
Total stock-based compensation	$ 433,004	$ 68,458
Research and development [Member]
Stock Compensation (Details) - Schedule of stock-based compensation expense [Line Items]
Total stock-based compensation	64,352	29,543
General and administrative [Member]
Stock Compensation (Details) - Schedule of stock-based compensation expense [Line Items]
Total stock-based compensation	367,702	17,315
Marketing and business development [Member]
Stock Compensation (Details) - Schedule of stock-based compensation expense [Line Items]
Total stock-based compensation	$ 950	$ 21,600

Related Party Transactions (Details) - USD ($)	1 Months Ended	12 Months Ended
Related Party Transactions (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Related Party Transactions (Details) [Line Items]
Amount billed for expense		$ 4,000
Percentage of employees cost		10.00%
Toray Industries, Inc. [Member]
Related Party Transactions (Details) [Line Items]
Cash paid	$ 249,040

- Definition

Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Related Party Transactions (Details) - Schedule of summarizes the amounts incurred - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Summarizes The Amounts Incurred [Abstract]
Expenses from LMBRI		$ 48,000
Expense Sharing Agreement payments to LMBRI		171,102
Amounts payable to LMBRI	2,000	2,000
Interest Incurred and Payments on Subordinated Notes to LMBRI (Note 4)		$ 3,303

Related Party Transactions (Details) - Schedule of amounts earned and due - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Amounts Earned And Due [Abstract]
Income from NanoHybrids included in Other Income	$ 163,256
Cash receipts from NanoHybrids	143,525
Amounts receivable from NanoHybrids included in Prepaids and Other Current Assets	$ 19,731

- Definition

Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

+ Details

Supplemental Balance Sheet Information (Details) - Schedule of prepaid expenses and other current assets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Prepaid Expenses and Other Current Assets [Abstract]
Prepaid insurance	$ 751,979	$ 1,127,062
Prepaid clinical trial expenses		160,467
Vendor prepayments	681,218	160,000
Prepaid other	240,283	165,179
Total prepaid expenses and other current assets	$ 1,673,480	$ 1,612,708

Supplemental Balance Sheet Information (Details) - Schedule of accrued expenses and other current liabilities - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Accrued Expenses and Other Current Liabilities [Abstract]
Accrued personnel costs	$ 533,577	$ 157,938
Accrued other	302,153	181,446
Total accrued expenses and other current liabilities	$ 835,730	$ 339,384

Property and Equipment (Details) - Schedule of property and equipment - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, total	$ 1,828,476	$ 786,203
Less: accumulated depreciation	(596,406)	(448,837)
Property and equipment, net	1,232,070	337,366
Construction in process [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, total	375,466	15,078
Furniture, fixtures, and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, total	$ 136,942	24,915
Furniture, fixtures, and equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciable lives	3 years
Furniture, fixtures, and equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciable lives	5 years
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciable lives	3 years
Property and equipment, total	$ 4,457	4,619
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, total	$ 1,268,380	741,591
Lab equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciable lives	3 years
Lab equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciable lives	5 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, depreciable lives	Life of lease
Property and equipment, total	$ 43,231

Leases (Details) - Schedule of lease arrangements for office and laboratory space	12 Months Ended
	Dec. 31, 2022 USD ($)
Schedule of lease arrangements for office and laboratory space [Abstract]
Weighted average remaining lease term – operating leases (in years)	3 years 8 months 12 days
Weighted average remaining lease term – finance leases (in years)	5 years 1 month 6 days
Weighted average discount rate	7.00%
Operating cash flows from operating leases (in Dollars)	$ 149,770

Leases (Details) - Schedule of lease assets and liabilities - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of lease assets and liabilities [Abstract]
Operating lease right-of-use asset	$ 465,514
Finance lease asset included in property & equipment, net	21,067
Total lease assets	486,581
Current portion of operating lease liability	168,706
Current portion of finance lease liability included in accrued expenses	4,807
Non-current operating lease liabilities	323,915
Non-current finance lease liabilities included in other non-current liabilities	15,823
Total lease liabilities	$ 513,251

Leases (Details) - Schedule of estimated lease payments	Dec. 31, 2022 USD ($)
Schedule of estimated lease payments [Abstract]
2023	$ 168,706
2024	162,991
2025	100,000
2026	100,000
2027	25,000
Thereafter
Total future lease payments	556,697
Less: Imputed interest	64,076
Present value of lease liability	$ 492,621

Commitments and Contingencies (Details)	12 Months Ended
Commitments and Contingencies (Details)	Dec. 31, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Purchase of goods	$ 800,000
Prepaid percentage	50.00%
Totaled approximately	$ 375,000
Aggregate amount	$ 700,000
Toray royalty commitment	the first sale of Cartridges, the Company will also make royalty payments to Toray equal to 15% of the net sales of the Cartridges for the period that any underlying patents exist or for 5 years after the first sale. Following the first sale, the Company will pay a one-time minimum royalty of $60,000, which shall be creditable against any royalties owed to Toray in such calendar year. The Company will pay a minimum royalty of $100,000 in each year thereafter, which are creditable against any royalties owed to Toray in such calendar year.

Income Tax (Details) - USD ($)	12 Months Ended
Income Tax (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Income Tax (Details) [Line Items]
Deferred tax assets	$ 2,700,000	$ 900,000
Operating loss carryforwards	11,200,000
Federal net operating losses	713,000
State net operating loss	$ 10,900,000	$ 6,300,000
Carried forward term	20 years	20 years
Amortized period	15 years
Prior To Two Thousand Eighteen [Member]
Income Tax (Details) [Line Items]
Federal net operating losses	$ 10,500,000

Income Tax (Details) - Schedule of company’s deferred tax assets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating losses	$ 3,043,585	$ 1,791,043
Tax credits	190,489	3,659
Intangible assets	66,716	68,564
Capitalized R&D expenses	1,018,165
Fixed assets	37,580
Other	272,106	97,945
Total deferred tax assets	4,628,641	1,961,211
Valuation allowance	(4,628,641)	(1,934,351)
Net deferred tax assets		26,860
Deferred tax liabilities:
Fixed assets		(26,860)
Net deferred tax assets		$ (26,860)

Income Tax (Details) - Schedule of statutory tax rates and the effective tax rates	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of statutory tax rates and the effective tax rates [Abstract]
Federal statutory rate	21.00%	21.00%
State income taxes, net of federal benefit and tax credits	6.86%	5.41%
Change in valuation allowance	(29.06%)	(25.88%)
Permanent differences	1.20%	(0.53%)
Effective tax rate	0.00%	0.00%